Radiation-Associated Liver Injury

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3 SUPPL., 2010, Pages

  Pan, Charlie C ^a   Kavanagh, Brian D ^b   Dawson, Laura A ^c   Li, X Allen ^d   Das, Shiva K ^e   Miften, Moyed ^b   Ten Haken, Randall K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Liver; Normal tissue toxicity; Radiation induced liver disease

Indexed keywords

DOSE-VOLUME EFFECTS; LIVER INJURIES; NORMAL-TISSUE TOXICITY; PLASMA PROTEIN; RADIATION THERAPY; RADIATION-INDUCED LIVER DISEASE; WASTE PRODUCTS; WHOLE BODY;

RADIATION; TOXICITY;

LIVER;

ALBUMIN; BILIRUBIN; BROXURIDINE; FLOXURIDINE;

ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CONTINUOUS INFUSION; DISEASE SEVERITY; HEPATIC ENCEPHALOPATHY; HEPATOBILIARY DISEASE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CANCER; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; LIVER SIZE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RISK FACTOR;

HUMANS; LIVER; LIVER NEOPLASMS; MODELS, BIOLOGICAL; RADIATION DOSAGE; RADIATION INJURIES; RADIATION TOLERANCE; RISK;

EID: 76449115024     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.092     Document Type: Article

References (41)

1. Yamasaki S.A., Marn C.S., Francis I.R., et al. High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. AJR Am J Roentgenol 165 (1995) 79-84
2. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 (1995) 1237-1248
3. Xu Z.-Y., Liang S.-X., Zhu J., et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 189-195
4. Kim T.H., Kim D.Y., Park J.-W., et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 67 (2007) 225-231
5. Cheng J.C.-H., Wu J.-K., Huang C.-M., et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54 (2002) 156-162
6. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
7. Kim J.H., Park J.W., Kim T.H., et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 813-819
8. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 (2002) 810-821
9. Shirato H., Seppenwoolde Y., Kitamura K., et al. Intrafractional tumor motion: Lung and liver. Semin Radiat Oncol 14 (2004) 10-18
10. Brock K.K., McShan D.L., Ten Haken R.K., et al. Inclusion of organ deformation in dose calculations. Med Phys 30 (2003) 290-295
11. Rosu M., Dawson L.A., Balter J.M., et al. Alterations in normal liver doses due to organ motion. Int J Radiat Oncol Biol Phys 57 (2003) 1472-1479
12. Dawson L.A., Brock K.K., Kazanjian S., et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 1410-1421
13. Guckenberger M., Sweeney R.A., Wilbert J., et al. Image-guided radiotherapy for liver cancer using respiratory-correlated computed tomography and cone-beam computed tomography. Int J Radiat Oncol Biol Phys 71 (2008) 297-304
14. Penna C., and Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am 82 (2002) 1075-1090 x-xi
15. Ingold J.A., Reed G.B., Kaplan H.S., et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93 (1965) 200-208
16. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
17. Russell A.H., Clyde C., Wasserman T.H., et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: Results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 27 (1993) 117-123
18. Liang S.-X., Zhu X.-D., Xu Z.-Y., et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65 (2006) 426-434
19. Hata M., Tokuuye K., Sugahara S., et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 182 (2006) 713-720
20. Wu D.H., Liu L., and Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 10 (2004) 2184-2189
21. Cheng J.C.-H., Wu J.-K., Lee P.C.-T., et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60 (2004) 1502-1509
22. Seong J., Park H.C., Han K.H., et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 55 (2003) 329-336
23. Jackson A., Ten Haken R.K., Robertson J.M., et al. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 31 (1995) 883-891
24. Dawson L.A., and Ten Haken R.K. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15 (2005) 279-283
25. Cheng J.C.-H., Liu H.-S., Wu J.-K., et al. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int J Radiat Oncol Biol Phys 62 (2005) 1150-1156
26. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 57 (2003) 113-119
27. Herfarth K.K., Hof H., Bahner M.L., et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57 (2003) 444-451
28. Mendez Romero A., Wunderink W., Hussain S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45 (2006) 831-837
29. Hoyer M., Roed H., Traberg Hansen A., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45 (2006) 823-830
30. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26 (2008) 657-664
31. Lee M.T., Kim J.J., Dinniwell R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27 (2009) 1585-1591
32. Yaes R.J., and Kalend A. Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys 14 (1988) 1247-1259
33. Schefter T.E., Kavanagh B.D., Timmerman R.D., et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62 (2005) 1371-1378
34. Kavanagh B.D., Schefter T.E., Cardenes H.R., et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 45 (2006) 848-855
35. Tai A., Erickson B., Khater K.A., et al. Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. Int J Radiat Oncol Biol Phys 70 (2008) 900-907
36. Park C., Papiez L., Zhang S., et al. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 847-852
37. Dawson L.A., Biersack M., Lockwood G., et al. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys 62 (2005) 829-837
38. Mitsunaga S., Kinoshita T., Kawashima M., et al. Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 730-735
39. Leibel S.A., Guse C., Order S.E., et al. Accelerated fractionation radiation therapy for liver metastases: Selection of an optimal patient population for the evaluation of late hepatic injury in RTOG studies. Int J Radiat Oncol Biol Phys 18 (1990) 523-528
40. Abrams R.A., Cardinale R.M., Enger C., et al. Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: Experience with Cisplatinum-based chemoradiotherapy in 76 patients. Int J Radiat Oncol Biol Phys 39 (1997) 1077-1085
41. Anscher M.S., Crocker I.R., and Jirtle R.L. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 122 (1990) 77-85